USD
+$0.00
(+0.00%
)At Close (As of Sep 16, 2025)
$1.23B
Market Cap
-
P/E Ratio
-3.16
EPS
$18.98
52 Week High
$6.50
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $258M |
Total Revenue | $258M |
Cost Of Revenue | $10M |
Costof Goods And Services Sold | $10M |
Operating Income | -$330M |
Selling General And Administrative | $120M |
Research And Development | $448M |
Operating Expenses | $588M |
Investment Income Net | - |
Net Interest Income | $48M |
Interest Income | $52M |
Interest Expense | $4M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $10M |
Income Before Tax | -$283M |
Income Tax Expense | $1M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$284M |
Comprehensive Income Net Of Tax | - |
Ebit | -$279M |
Ebitda | -$269M |
Net Income | -$283M |
Field | Value (USD) |
---|---|
Total Assets | $1.2B |
Total Current Assets | $1B |
Cash And Cash Equivalents At Carrying Value | $150M |
Cash And Short Term Investments | $150M |
Inventory | - |
Current Net Receivables | $25M |
Total Non Current Assets | $134M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | $14M |
Short Term Investments | $828M |
Other Current Assets | $13M |
Other Non Current Assets | - |
Total Liabilities | $665M |
Total Current Liabilities | $226M |
Current Accounts Payable | $18M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $12M |
Total Non Current Liabilities | $439M |
Capital Lease Obligations | $12M |
Long Term Debt | $48M |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $60M |
Other Current Liabilities | $110M |
Other Non Current Liabilities | $157M |
Total Shareholder Equity | $485M |
Treasury Stock | - |
Retained Earnings | -$1.1B |
Common Stock | $1.6B |
Common Stock Shares Outstanding | $90M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$170M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $10M |
Capital Expenditures | $6M |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$84M |
Cashflow From Financing | $277M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$283M |
Field | Value (USD) |
---|---|
Gross Profit | $258M |
Total Revenue | $258M |
Cost Of Revenue | $10M |
Costof Goods And Services Sold | $10M |
Operating Income | -$330M |
Selling General And Administrative | $120M |
Research And Development | $448M |
Operating Expenses | $588M |
Investment Income Net | - |
Net Interest Income | $48M |
Interest Income | $52M |
Interest Expense | $4M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $10M |
Income Before Tax | -$283M |
Income Tax Expense | $1M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$284M |
Comprehensive Income Net Of Tax | - |
Ebit | -$279M |
Ebitda | -$269M |
Net Income | -$283M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. The company is headquartered in Hayward, California.